Expert oncologists review key datasets in leukemia & lymphoma that were presented at the ASCO 2022 and EHA 2022 Annual Meetings.
EP. 1: Acute Lymphocytic Leukemia Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings
Expert oncologist perspectives on key clinical trial data in acute lymphocytic leukemia from the ASCO 2022 and EHA 2022 Annual Meetings.
EP. 2: Lymphomas Trial Data From the ASCO 2022 and EHA 2022 Annual Meetings
Shared insight from expert oncologists on key clinical trial data in lymphomas from the ASCO 2022 and EHA 2022 Annual Meetings.
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer
Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC
Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer
Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC